Skip to Content
  • A 2.3 Billion Dollar Attention-Getter

    No sooner do I write another post about pharma marketing than Pfizer finds itself paying 3.2 2.3 billion dollars in fines for doing it improperly. 1.2 billion o… Read More
  • REACH for the Sky!

    I wrote years ago on this blog about REACH, the European program to (as the acronym has it) Register, Evaluate, Authorize and Restrict Chemical substances. (I&# Read More
  • The PhRMA Deal

    I’m not always a fan of John Boehner, but I think he’s on the right track with his letter to Billy Tauzin (PDF here from NPR’s health care sit… Read More
  • PhRMA’s Negotiating Game

    Now for a bit on the pharma industry and the current fight over health care legislation. Does the industry want a new system to come into force, or not? Depends… Read More
  • Savient Feels The Pains of Gout

    Well, here’s a nasty surprise for you: your new drug gets a 14 to 1 “Yes” vote from an FDA advisory committee, but the agency turns you down,… Read More
  • Health Care Reform – Really?

    I haven’t written about the various health care reform packages that are being hammered out and hammered through the various parts of Congress. That’… Read More
  • Vanda Comes Back From the Dead

    I wrote last summer about Vanda Pharmaceuticals and their difficulty getting a new antipsychotic Fanapt (iloperidone) through the FDA. At the time, they’d… Read More
  • Selling Zyprexa

    Well, this doesn’t look good for Lilly. A huge pile of court documents has been unsealed in the ongoing lawsuits about Zyprexa’s off-label promotion… Read More
Page 22 of 24« First...10...2021222324